These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28077575)

  • 1. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
    Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
    J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
    Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
    Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG2m4, an engineered antibody isotype with reduced Fc function.
    An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
    MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
    Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
    Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc-engineered antibodies with immune effector functions completely abolished.
    Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
    PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
    Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
    J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
    Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
    Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
    Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
    MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
    van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
    Front Immunol; 2019; 10():548. PubMed ID: 30967872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.